A Phase 3 interventional study of In-house Hepatitis B Vaccine and Registered Hepatitis B Vaccine in Vaccination Adverse Event and Immunogenicity, Vaccine, sponsored by PT Bio Farma. Not yet recruiting. Open to participants aged 0 Days to 3 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by PT Bio Farma · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial is a randomized, double-blind, two arms parallel groups, prospective intervention study.
This trial is a randomized, double-blind, two arms parallel groups, prospective intervention study.
Approximately 270 newborns will be enrolled in this trial, divided into 2 arms, with the ratio 1:1. The subject will receive one dose of In-House Recombinant Hepatitis B at birth or registered monovalent Hepatitis B as a control then followed by registered DTwP-HepB-IPVHib (HEXASIIL) vaccine
1,047 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.
This study's planned enrollment of 270 is above the median of 145 across 757 interventional studies indexed under Hepatitis B.
Browse Hepatitis B studies →PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0,5 ml of In-house Recombinant Hepatitis B (Bio Farma) vaccine injected at birth
Biological: In-house Hepatitis B Vaccine
0,5 ml of Regstered Hepatitis B (Bio Farma) vaccine injected at birth
Biological: Registered Hepatitis B Vaccine
0,5 ml In-House Recombinant Hepatitis B (Bio Farma) vaccine injected approximately at birth. The vaccines will be injected intramuscularly into the right anterolateral thigh
0,5 ml Registered Recombinant Hepatitis B (Bio Farma) vaccine injected approximately at birth. The vaccines will be injected intramuscularly into the right anterolateral thigh
Protectivity of primary series In-House Recombinant Hepatitis B vaccine
Percentage of subjects with anti HBsAg \> 10mIU/ml after the completion of the primary series of recombinant hepatitis B and Registered DTwP-HepB-IPV-Hib (HEXASIIL) vaccine for each group
Time frame: 28 days after administration of third dose of DTwP-HepB-IPV-Hib (HEXASIIL) vaccine
Immunogenicity of birth dose In-House Recombinant Hepatitis B vaccine
GMT and percentage of infants with increasing antibody titer ≥ 4 times and/ or percentage of infants with transition of seronegative to seropositive after birth dose Hep B vaccine
Time frame: 28 days after administration of Hep B birth dose vaccine
Immunogenicity of In-House recombinant Hepatitis B vaccine after the completion of Registered DTwP-HepB-IPV-Hib (HEXASIIL) vaccine
GMT and percentage of infants with increasing antibody titer ≥ 4 times and/ or percentage of infants with transition of seronegative to seropositive after completion of Registered DTwP-HepB-IPV-Hib (HEXASIIL) vaccine
Time frame: 28 days after the third dose of DTwP-HepB-IPV-Hib (HEXASIIL) vaccine
Safety of In-House Recombinant Hepatitis B vaccine
Percentage of subjects with solicited and unsolicited adverse events after each dose
Time frame: 30 minutes, 7 days, 28 days after each dose
Serious Adverse Events
Percentage of infants with at least one serious adverse events
Time frame: 28 days after third dose of Registered DTwP-HepB-IPV-Hib (HEXASIIL) vaccine administration
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.
Of 42 industry-sponsored phase 3 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 4 months is below that.
Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.